CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nebulized Sterile SalineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug1722 MenACWY boost Wiki 1.00
drug1847 Nebulized Platelet Lysate Wiki 1.00
drug641 ChAdOx1 nCoV-19 half boost Wiki 1.00
drug2053 Paracetamol Wiki 1.00
drug640 ChAdOx1 nCoV-19 full boost Wiki 1.00
drug1721 MenACWY Wiki 1.00
drug636 ChAdOx1 nCoV-19 Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome

To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.

NCT04487691 Covid19 Biological: Nebulized Platelet Lysate Other: Nebulized Sterile Saline

Primary Outcomes

Description: Changes in pre and post treatment spirometry measures

Measure: Spirometry-FVC and FEV1/FVC tests

Time: 4 weeks; 8 weeks

Secondary Outcomes

Description: Changes from pre and post treatment spirometry measures

Measure: Spirometry-FVC and FEV1/FVC tests

Time: 3 months, 6 months

Description: Changes in distance walked during 6MWD test from pre to post treatment

Measure: 6 Minute Walk Distance test (6MWD)

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Changes in distance-desaturation product from 6MWD from pre to post treatment

Measure: Distance-desaturation product from 6MWD

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Changes in San Diego Shortness of Breath Questionnaire (SOBQ) score from pre to post; treatment; scores range from 0-120 with higher scores equaling greater breathing impairment

Measure: San Diego Shortness of Breath Questionnaire (SOBQ)

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Changes in SF-36 scores from pre to post treatment; 8 subscales 0-100 range where lower scores equal more disability

Measure: Short Form-36 (SF-36)

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Average SANE score post treatment; scores range from 0-100 where 0=no improvement and 100=100% improvement in breathing condition

Measure: Modified Single Assessment Numeric Evaluation (SANE)

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: changes in medications from pre to post treatment

Measure: Medications

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Incidence of adverse events after treatment

Measure: Incidence of adverse events

Time: 4 weeks; 8 weeks; 3 months; 6 months

Description: Incidence of surgical/other treatment interventions after treatment

Measure: Incidence of surgical/other treatment interventions

Time: 4 weeks; 8 weeks; 3 months; 6 months

No related HPO nodes (Using clinical trials)